James Rodberg Biography and Net Worth

CFO of Sight Sciences

Mr. Rodberg was appointed Chief Financial Officer of Sight Sciences effective November 2025.

Previously, he served as Sight Sciences’ Vice President of Finance and Corporate Controller since joining the Company in early 2021 prior to its IPO. He also served as interim CFO at Sight Sciences in 2023. Mr. Rodberg has 20 years of public accounting and company finance leadership experience. Prior to joining Sight Sciences, he served as VP, FP&A at nVent Electric, Director of Finance at Abbott Laboratories and had several progressive finance and accounting roles at St. Jude Medical (prior to its acquisition by Abbott). He began his career at Deloitte in the audit and assurance practice. He received a B.S. in Accounting from the University of Minnesota and is a Certified Public Accountant (inactive).

What is James Rodberg's net worth?: The estimated net worth of James Rodberg is at least $1.22 million as of April 6th, 2026. Mr. Rodberg owns 230,939 shares of Sight Sciences stock worth more than $1,216,125 as of May 7th. This net worth approximation does not reflect any other assets that Mr. Rodberg may own. Learn More about James Rodberg's net worth.
How do I contact James Rodberg?: The corporate mailing address for Mr. Rodberg and other Sight Sciences executives is 4040 CAMPBELL AVE SUITE 100, MENLO PARK CA, 94025. Sight Sciences can also be reached via phone at 877-266-1144 and via email at [email protected]. Learn More on James Rodberg's contact information.
Has James Rodberg been buying or selling shares of Sight Sciences?: During the past quarter, James Rodberg has sold $25,670.05 of Sight Sciences stock. Most recently, James Rodberg sold 7,231 shares of the business's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $3.55, for a transaction totalling $25,670.05. Following the completion of the sale, the chief financial officer now directly owns 230,939 shares of the company's stock, valued at $819,833.45. Learn More on James Rodberg's trading history.
Who are Sight Sciences' active insiders?: Sight Sciences' insider roster includes David Badawi (Founder & Chief Technology Officer), Alison Bauerlein (CFO), Staffan Encrantz (Director), James Rodberg (CFO), Jesse Selnick (CFO), and Brenton Taylor (Executive Vice President, Operations and R&D). Learn More on Sight Sciences' active insiders.
Are insiders buying or selling shares of Sight Sciences?: In the last year, insiders at the sold shares 30 times. They sold a total of 307,648 shares worth more than $1,746,086.49. The most recent insider tranaction occured on April, 6th when CFO James Rodberg sold 7,231 shares worth more than $25,670.05. Insiders at Sight Sciences own 30.9% of the company. Learn More about insider trades at Sight Sciences.
Information on this page was last updated on 4/6/2026.

James Rodberg Insider Trading History at Sight Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/6/2026	Sell	7,231	$3.55	$25,670.05	230,939
1/16/2026	Sell	2,616	$6.62	$17,317.92	151,230
1/6/2026	Sell	594	$7.48	$4,443.12	153,846
1/5/2026	Sell	4,405	$7.82	$34,447.10	154,440

James Rodberg Buying and Selling Activity at Sight Sciences

Sight Sciences Company Overview

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Today's Range

Now: $5.36

$4.36

$5.40

50 Day Range

MA: $4.07

$3.45

$5.62

2 Week Range

Now: $5.36

$2.81

$9.24

Volume

300,522 shs

Average Volume

317,056 shs

Market Capitalization

$291.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38